The antibody-drug conjugate brentuximab vedotin is effective as a frontline therapy for Hodgkin lymphoma patients over age 60 who are unfit for chemotherapy.
Hematologic Cancer Targets
The FDA recently granted priority review status to ixazomib (Takeda) for the treatment of relapsed or refractory multiple myeloma.
Treatment with a short course of vemurafenib was effective and rapid in patients with relapsed or refractory hairy-cell leukemia, resulting in overall response rates of over 95%.
Combined treatment with lenalidomide/rituximab resulted in better clinical response in patients with recurrent follicular lymphoma than did lenalidomide alone.
Daratumumab, a monoclonal antibody that targets CD38, was safe and effective in patients with heavily pretreated and refractory multiple myeloma.
Using a gene expression-based assay on formalin-fixed paraffin-embedded tissue, researchers were able to identify groups among DLBCL patients with significantly different outcomes from R-CHOP treatment.
Ponatinib yielded complete cytogenetic responses in most patients with newly diagnosed chronic-phase CML, but the risk of vascular events suggests other agents should first be considered.
Adding vosaroxin to cytarabine resulted in no significant improvement in overall survival in patients with relapsed or refractory acute myeloid leukemia, but the trial did suggest that vosaroxin could be an option for salvage therapy in patients aged 60 and older.
Eighty percent of patients with advanced multiple myeloma had a clinical response to a new T cell–receptor therapy that used T cells to target cells expressing NY-ESO-1.
The FDA approved the proteasome inhibitor carfilzomib for the treatment of multiple myeloma, when used in combination with lenalidomide and dexamethasone.